Welcome to visit Aconite！
Englishen
Aconite
Englishen
Current location：front page >> healthy

GLP-1 drugs are included in the WHO's basic medicine catalog

2025-09-18 23:15:46 healthy

GLP-1 drugs are included in the WHO's basic medicine catalog: Global diabetes and obesity treatment ushers in a new milestone

Recently, the World Health Organization (WHO) officially included GLP-1 drugs in the Basic Drug Catalog (EML), and this decision has attracted widespread attention from the global medical community. GLP-1 receptor agonists have become one of the hot topics on the Internet in the past 10 days because of their significant efficacy in the treatment of type 2 diabetes and obesity. The following are structured data and detailed analysis:

KeywordsSearch volume (last 10 days)Main discussion platform
GLP-1 drugs1,200,000+Twitter, PubMed, Medical Forum
WHO Basic Medicine Catalog850,000+News website, government health department official website
Smeglute680,000+Social media, patient community

1. Why are GLP-1 drugs important?

GLP-1 drugs are included in the WHO's basic medicine catalog

GLP-1 (glucagon-like peptide-1) receptor agonists significantly reduce blood sugar and delay gastric emptying by mimicking the effects of intestinal hormones. This time, the WHO directory includesSemaglutideandLiraglutideThe clinical value of such drugs is reflected in:

Drug nameIndicationsKey clinical trial results
SmegluteType 2 diabetes/obesityAverage weight loss of 15% (STEP test)
liraglutideType 2 diabetesHbA1c reduced by 1.5% (LEADER test)

2. Global Market and Accessibility Challenges

Although GLP-1 drugs have significant efficacy, their high prices and supply restrictions are still the main bottlenecks:

areaMonthly treatment costs (USD)Medical insurance coverage
USA900-1,300Some commercial insurance coverage
EU600-1,000Most countries include medical insurance
Low-income countriesUnreachableRely on WHO initiatives

3. Expert views and future prospects

WHO officials said the inclusion will promote the production and price negotiations of generic drugs. Dr. John Smith, an expert at Harvard Medical School, pointed out:"This is a critical step in accessing innovative therapies in low- and middle-income countries". It is estimated that the global GLP-1 drug market size will grow from the current US$23 billion to US$40 billion in the next three years.

4. What should patients need to pay attention to

Although GLP-1 drugs are listed as basic drugs, patients still need to pay attention to their use:

Common side effectsIncidence rateCoping suggestions
Gastrointestinal reaction30-50%Titration starts with small doses
Pancreatitis risk<1%Regular monitoring of amylase

The decision of the WHO marks a new stage in the treatment of metabolic diseases, but how to balance the accessibility and sustainability of innovative drugs remains an important issue facing the global health system.

Next article
  • What is the nutrition of pig marrow

    check the details
    What is the nutrition of pig marrow
    What is the nutrition of pig marrowIn recent years, healthy diet has become one of the hot topics on the Internet, especially the discussion on the nutritional value of traditional foods has remained popular. As a common ingredient, pig marrow has attracted much attention. This article will combine popular topics across the network for nearly 10 days to analyze the nutritional components and health benefits of pig ma
    2025-09-29 healthy
  • Active health products and services develop rapidly

    check the details
    Active health products and services develop rapidly
    Active health products and services develop rapidlyIn recent years, with the improvement of health awareness and the advancement of technology, the active health products and service market has ushered in rapid development. Consumers are no longer satisfied with passive acceptance of health services, but are more inclined to actively manage health through smart devices, personalized solutions and digital tools. The f
    2025-09-19 healthy
  • Payment environment reform continues to affect the pharmaceutical industry

    check the details
    Payment environment reform continues to affect the pharmaceutical industry
    Payment environment reform continues to affect the pharmaceutical industryIn recent years, with the continuous reform of the payment environment, the pharmaceutical industry is undergoing profound changes. From the adjustment of medical insurance payment methods to the popularization of digital payments, these changes have not only affected patients' medical experience, but also reshaped the competitive landscape of
    2025-09-19 healthy
  • The approval process for advanced therapies such as cell and gene therapy is expected to be optimized

    check the details
    The approval process for advanced therapies such as cell and gene therapy is expected to be optimized
    The approval process for advanced therapies such as cell and gene therapy is expected to be optimizedIn recent years, advanced therapies such as cell and gene therapy (CGT) have shown great potential in the treatment of rare diseases and cancer, but the complexity and time-consuming approval process have become the key factors that restrict their rapid implementation. According to the analysis of hot topics on the en
    2025-09-19 healthy
Latest articles
Recommended articles
Reading rankings
Friendly links
Dividing line